Showing results (61-70 of 69) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
British Journal of Haematology|April 21, 2015
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative dataSusan E Bates, Robin Eisch, Alexander Ling, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOPJoo Y Song, Anamarija M Perry, Alex F Herrera, et al.Cancer Immunology Research|October 23, 2020
The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic LymphomaXiuli Wang, Christian Huynh, Ryan Urak, et al.Blood Advances|October 12, 2021
Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphomaAlex F Herrera, Joycelynne Palmer, Vikram Adhikarla, et al.Human Gene Therapy|April 30, 2014
Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013Marina O'Reilly, Howard J Federoff, Yuman Fong, et al.Nature Medicine|December 18, 2021
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Hale Fowler, Michael Dickinson, Martin Dreyling, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2017
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor LymphomaAlex F Herrera, Scott J Rodig, Joo Y Song, et al.Blood|January 9, 2024
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial updateMartin Dreyling, Nathan Hale Fowler, Michael Dickinson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F Herrera, Matthew Mei, Lawrence Low, et al.Pageof 7